Results 11 to 20 of about 31,041 (297)
British Journal of Haematology, 2008 SummaryPlatelets play a major role in thromboembolic diseases, and so antiplatelet therapy remains crucial in treatment and prophylaxis. Upon vascular injury, platelets rapidly adhere to the exposed subendothelial matrix, after which they become activated, resulting in the recruitment of additional platelets from the circulation to eventually form a ...
Katleen Broos +4 more
openaire +4 more sources
British Journal of Pharmacology, 2006 British Journal of Pharmacology (2006) 147, S241–S251.
Gustav Victor Rudolf Born, Carlo Patrono
openaire +3 more sources
Precision antiplatelet therapy
Research and Practice in Thrombosis and Haemostasis, 2023 A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire +2 more sources
Multivessel Percutaneous Coronary Intervention in a Patient With Bernard-Soulier Syndrome
JACC: Case Reports, 2020 Bernard-Soulier syndrome, a congenital bleeding disorder, can rarely present with atherosclerosis and thrombosis. Acute coronary syndrome in such patients present a unique challenge as no standard set of guidelines exist for successful treatment.
Osman Faheem, MD +4 more
doaj +1 more source
Pharmacogenetics of Antiplatelet Drugs [PDF]
The Scientific World JOURNAL, 2002 Pharmacogenetics refers to the genetic factors that influence the response to a drug, often involving genetic variations in drug metabolizing enzymes. The pharmacogenetics of antiplatelet agents is in its infancy and largely reflects variations in drug targets or related genes.
Ronan Curtin, Desmond J. Fitzgerald
openaire +3 more sources
Gut and Liver, 2018 Background/AimsCurrent guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding.Methods : Gastric ESD cases with ...
Sooyeon Oh +10 more
doaj +1 more source
Архивъ внутренней медицины, 2017 Study objective. To assess the peculiarities of hospitalization of patients with AF in combination with CHD in the departments of the general therapeutic profile of a multidisciplinary hospital, the frequency of complications of various forms of AF, to ...
V. P. Mikhin +2 more
doaj +1 more source
BMC Neurology, 2021 Background We tried to evaluate the prevalence of premature discontinuation of antiplatelets and its affecting factors after ischemic stroke using large-sized representative national claims data.
Seung Jae Kim +5 more
doaj +1 more source
BJGP Open, 2022 Background: Patients with both atrial fibrillation (AF) and cardiovascular disease (CVD) may receive dual antithrombotic therapy (DAT) with both an anticoagulant and ≥1 antiplatelet agents.
Charis Xuan Xie +5 more
doaj +1 more source
Antiplatelets and Anticoagulants [PDF]
Clinical Cardiology, 2010 AbstractThose of us who see patients with cardiovascular disorders frequently use antiplatelet and anticoagulant agents; the common agents are aspirin, clopidogrel, and warfarin. This editorial is a personal viewpoint about commonly used drugs, not so commonly used drugs, and drugs that are yet to be used clinically. Copyright © 2010 Wiley Periodicals,
openaire +3 more sources